AKT3 and Neonatal sepsis: Based on this, future studies can develop small molecule inhibitors or RNA interference technology specifically targeting EMX2OS/miR-654-3p/AKT3 axis, which may provide a new treatment strategy for improving the prognosis of neonatal sepsis.